Treatment of High-Risk Sickle Cell Disease (SCD) with Familial Haploidentical (FHI) T- Cell Depleted (TCD) Stem Cell Transplantation with T-Cell Addback (IND 14359)  Cori Abikoff, MD, Julie-An Talano, MD, Carolyn Keever-Taylor, PhD, Mark Walters, MD, Shalini Shenoy, MD, Theodore B. Moore, MD, Susan K. Parsons, MD, MRP, Allen J. Dozor, MD, Deborah Friedman, MD, Ramanamoorthy Chitti, MD, Qiuhu Shi, PhD, Brenda Grossman, MD, Rona Weinberg, PhD, Erin Morris, RN, BSN, Phyllis Brand, RN, MPH, Sandra Fabricatore, RN, MSN, CPNP, Olga Militano, PharmD, Janet Ayello, MS, MT(ASCP), Mildred Semidei-Pomales, MS, Lee Ann Baxter-Lowe, PhD, Mitchell S. Cairo, MD  Biology of Blood and Marrow Transplantation  Volume 21, Issue 2, Pages S90-S91 (February 2015) DOI: 10.1016/j.bbmt.2014.11.110 Copyright © 2015 Terms and Conditions

Figure 1 Childhood and Adolescent and Young Adult Familial Haploidentical AlloSCT Sickle Cell Disease Consortium. Biology of Blood and Marrow Transplantation 2015 21, S90-S91DOI: (10.1016/j.bbmt.2014.11.110) Copyright © 2015 Terms and Conditions

Figure 2 Patient Outcomes. Biology of Blood and Marrow Transplantation 2015 21, S90-S91DOI: (10.1016/j.bbmt.2014.11.110) Copyright © 2015 Terms and Conditions